TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6144266

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydralazine after furosemide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 30656454

Group type: EXPERIMENTAL
Intervention: Simple curriculum including theoretical and practical training for laparoscopic salpingectomy.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 20
Study: 29867230

Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Atezolizumab (monotherapy)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 305
Study: 25990196

Group type: EXPERIMENTAL
Intervention: Focal muscle vibration (FMV) treatment according to the 'repeated muscle vibration' protocol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 50
Study: 23440143

Group type: EXPERIMENTAL
Intervention: Supervised physical exercise and nutritional guidance program (3 times a week for 12 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 22074834

Group type: EXPERIMENTAL
Intervention: Class II Division 1 malocclusion (CL2 group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Class I normal occlusion (CL1 group)
Number of subjects: 120
Study: 19058081

Group type: EXPERIMENTAL
Intervention: Helix aspersa extract cream applied twice daily for a maximum period of 14 days or until full epithelialization
Number of subjects: 27

Group type: COMPARATOR
Intervention: Moist exposure burn ointment (MEBO)
Number of subjects: 27
Study: 17365757

Group type: EXPERIMENTAL
Intervention: Proactive telephone counseling intervention
Number of subjects: 1058
Study: 15643550

Group type: EXPERIMENTAL
Intervention: BSE-018 with a high-fat meal (treatment B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BSE-018 in the fasted state (treatment A)
Number of subjects: 0
Study: 11441425

Group type: EXPERIMENTAL
Intervention: Butorphanol (0.5, 1, and 2 mg/70 kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Morphine (2.5, 5, and 10 mg/70 kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nalbuphine (2.5, 5, and 10 mg/70 kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pentazocine (7.5 and 15 mg/70 kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study: 9883777

Group type: EXPERIMENTAL
Intervention: Web-based educational tools (multimedia course modules)
Number of subjects: 164
Study: 9075778

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 350 mg/m2 as intravenous bolus injection plus folinic acid (FA) 200 mg/m2 and interferon 5 x 10(6) U/m2 (regimen A)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 500 mg/m2 as 2-hour infusion plus folinic acid (FA) 200 mg/m2 and interferon 5 x 10(6) U/m2 (regimen B)
Number of subjects: 76
Study: 16296710

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once daily, adjusted to 10 mg after 2 weeks if necessary)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7019407

Group type: EXPERIMENTAL
Intervention: Oxacillin plus sisomicin and carbenicillin (treatment group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oxacillin alone (control group)
Number of subjects: 24
Study: 30378465

Group type: COMPARATOR
Intervention: High-dose caffeine (10 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moderate-dose caffeine (4 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Repeated-dose caffeine (2 mg/kg before each match to a total of 10 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Selective caffeine administration (6.16 ± 1.58 mg/kg)
Number of subjects: 12
Study: 30202508

Group type: EXPERIMENTAL
Intervention: Robotic intervention using the robot 'CommU'
Number of subjects: 68

Group type: COMPARATOR
Intervention: Human agent intervention
Number of subjects: 68
Study: 26152757

Group type: EXPERIMENTAL
Intervention: Central BP intervention (CBP)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 286
Study: 23797624

Group type: EXPERIMENTAL
Intervention: Clonidine 1 μg/kg added to 2% lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% Lidocaine (Control)
Number of subjects: 40
Study: 22465650

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 80

Group type: COMPARATOR
Intervention: Glidescope
Number of subjects: 80
Study: 20565999

Group type: EXPERIMENTAL
Intervention: High protein, carbohydrate-free (HP-0C; 30, 0 and 70 En%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: High protein (HP; 30, 40 and 30 En%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal protein (NP; 10, 60 and 30 En%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal protein, glycogen-lowering exercise (NP-g; 10, 60 and 30 En%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: High protein (HP) vs Normal protein (NP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: High protein, carbohydrate-free (HP-0C) vs High protein (HP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High protein, carbohydrate-free (HP-0C) vs Normal protein (NP-g)
Number of subjects: 45
Study: 17629719

Group type: EXPERIMENTAL
Intervention: r-metHuGDNF via continuous bilateral intraputaminal infusion
Number of subjects: 34
Study: 16140442

Group type: EXPERIMENTAL
Intervention: Longitudinal incision closed with Z-plasties
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified Bruner incision closed by Y-V plasties
Number of subjects: 0
Study: 12805964

Group type: EXPERIMENTAL
Intervention: Quinfamide treatment (4.3 g/kg dose) administered at 3- or 6-month intervals.
Number of subjects: 302
Study: 9764615

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 microg every 4 hours)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microg every 4 hours)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Oral and Vaginal misoprostol
Number of subjects: 206
Study: 8181333

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide added to albuterol sulfate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Albuterol alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide in open study
Number of subjects: 20
Study: 3372885

Group type: EXPERIMENTAL
Intervention: Objective Structured Clinical Examination (OSCE)
Number of subjects: 0
Study: 30393104

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) at doses of 50 mg, 75 mg, and 100 mg, with training (reviewed IFU and shown how to inject)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Testosterone enanthate (TE) at doses of 50 mg, 75 mg, and 100 mg, without training (only given IFU)
Number of subjects: 123
Study: 27167852

Group type: EXPERIMENTAL
Intervention: Structured protocol model
Number of subjects: 1252

Group type: COMPARATOR
Intervention: Clinical acumen model
Number of subjects: 1252
Study: 24781225

Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard treatment with antidepressants and antipsychotics
Number of subjects: 192
Study: 22835841

Group type: EXPERIMENTAL
Intervention: Extinction treatment in three contexts (BCD)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Extinction treatment in one context (B)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (same context as extinction)
Number of subjects: 68
Study: 20555288

Group type: EXPERIMENTAL
Intervention: Estrogen + Testosterone (40 mg testosterone undecanoate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Estrogen + Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Estrogen + Testosterone
Number of subjects: 50
Study: 18482290

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (50 mg daily for 1 year)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 15933240

Group type: EXPERIMENTAL
Intervention: Intervention (fruit and vegetable consumption, multivitamin intake, red meat consumption, physical activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 14750614

Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg once daily for 5 days)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg twice daily for 10 days)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 593
Study: 10501246

Group type: EXPERIMENTAL
Intervention: Intranasal vaccine composed of native outer membrane vesicles (NOMV)
Number of subjects: 32
Study: 8689808

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 1326012

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foscarnet
Number of subjects: 0
Study: 6731753

Group type: EXPERIMENTAL
Intervention: Conjuvac (dialysed aqueous extract of pollens chemically conjugated to activated sodium alginate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Allpyral (pyridine-extracted alum-precipitated crude extract)
Number of subjects: 40
Study: 30366115

Group type: EXPERIMENTAL
Intervention: Proximal Tubal Occlusion (PTO)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Salpingectomy
Number of subjects: 165
Study: 28590525

Group type: EXPERIMENTAL
Intervention: 500 U abobotulinumtoxinA
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 1,000 U abobotulinumtoxinA
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 1,500 U abobotulinumtoxinA
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Repeated injections of abobotulinumtoxinA
Number of subjects: 258
Study: 27039205

Group type: EXPERIMENTAL
Intervention: White wine with ≤15% alcohol content twice a day for 3-4 weeks
Number of subjects: 141

Group type: COMPARATOR
Intervention: Nutritional supplement (such as Boost® or Ensure®)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: White wine with ≤15% alcohol content
Number of subjects: 141
Study: 24413342

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) treatment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mindfulness treatment
Number of subjects: 81
Study: 21805588

Group type: EXPERIMENTAL
Intervention: ECG patterns indicating LAD occlusion
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: ECG patterns indicating RCA and LCx involvement
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Study threshold for ST-segment elevation
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Reciprocal ST-segment depression prevalence
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: LBBB cases
Number of subjects: 3602

Group type: EXPERIMENTAL
Intervention: Left main coronary occlusions
Number of subjects: 3602
Study: 21122516

Group type: EXPERIMENTAL
Intervention: Oral plus enema mesalazine treatment (PINCE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral mesalazine treatment alone (Control)
Number of subjects: 0
Study: 17381912

Group type: EXPERIMENTAL
Intervention: Vouchers exchangeable for fruit juice
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Advice group (midwives' advice and leaflets)
Number of subjects: 190
Study: 16269638

Group type: EXPERIMENTAL
Intervention: Standard treatment plus thermal stimulation (TS) for 30 minutes daily for 6 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard rehabilitation treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Standard treatment plus thermal stimulation (TS)
Number of subjects: 46
Study: 12412828

Group type: EXPERIMENTAL
Intervention: 1000 mg of mycophenolate mofetil alone (treatment 1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1000 mg of mycophenolate mofetil and 2400 mg of calcium polycarbophil (treatment 2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1000 mg of mycophenolate mofetil and 2400 mg of calcium polycarbophil with 30 mg of lansoprazole for 5 days (treatment 3)
Number of subjects: 6
Study: 9706948

Group type: EXPERIMENTAL
Intervention: Tramadol (1.25 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Codeine (1 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine (0.125 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 7596854

Group type: EXPERIMENTAL
Intervention: Transvenous lead system
Number of subjects: 48
Study: 2120201

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 40
Study: 312297

Group type: EXPERIMENTAL
Intervention: salsalate (salicylsalicylic acid) 3000 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: aspirin 3900 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 30730896

Group type: EXPERIMENTAL
Intervention: CPA-related stress group (n = 45)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 28422463

Group type: COMPARATOR
Intervention: Manual Toothbrush (MTB) alone
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Manual Toothbrush (MTB) plus String Floss (SF)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Manual Toothbrush (MTB) plus Philips Sonicare AirflossPro with Cool Mint Listerine® Antiseptic (AFPL)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Manual Toothbrush (MTB) plus Philips Sonicare AirflossPro with BreathRx™ (AFPB)
Number of subjects: 290
Study: 25139195

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23305980

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intermittent normoxic training (INT)
Number of subjects: 9
Study: 21628399

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 555

Group type: COMPARATOR
Intervention: Crossover cohort (switching from deferoxamine to deferasirox)
Number of subjects: 555
Study: 19337257

Group type: EXPERIMENTAL
Intervention: Immunochemical faecal occult blood testing (FIT) at cut-off 75 ng/ml
Number of subjects: 10011

Group type: COMPARATOR
Intervention: Guaiac-based faecal occult blood test (gFOBT)
Number of subjects: 10011

Group type: EXPERIMENTAL
Intervention: Immunochemical faecal occult blood testing (FIT) at varying cut-off levels (50-200 ng/ml)
Number of subjects: 10011
Study: 16234288

Group type: EXPERIMENTAL
Intervention: 1.0 microg/kg pegylated interferon alpha‐2b
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg pegylated interferon alpha‐2b
Number of subjects: 16
Study: 15273177

Group type: EXPERIMENTAL
Intervention: Mouthguards
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 301

Group type: COMPARATOR
Intervention: Non-users of headgear
Number of subjects: 301

Group type: COMPARATOR
Intervention: Non-users of mouthguards
Number of subjects: 301
Study: 11125531

Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: No practice
Number of subjects: 0
Study: 9314346

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8323338

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 400 micrograms/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 800 micrograms/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (wash out periods)
Number of subjects: 19
Study: 3521767

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen, 40 mg daily for three years
Number of subjects: 179

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 179
Study: 30307466

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Chemotherapy (FEC100 followed by docetaxel)
Number of subjects: 106
Study: 26454185

Group type: EXPERIMENTAL
Intervention: Behavioral activation (5 weekly sessions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (age-matched, low BDI-II score)
Number of subjects: 15
Study: 25391006

Group type: EXPERIMENTAL
Intervention: RBV for 4 weeks followed by combined therapy with peg‐IFN alpha‐2a + RBV for 48 weeks (n = 73)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Combined therapy with peg‐IFN alpha‐2a + RBV for 48 weeks (n = 30)
Number of subjects: 103
Study: 22544891

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg once daily plus tiotropium 18 μg once daily
Number of subjects: 2276

Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily
Number of subjects: 2276
Study: 20844613

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 150 × 10^6 autologous bone marrow mononuclear cells
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 19157158

Group type: EXPERIMENTAL
Intervention: Linear polarized near-infrared light (PL) irradiation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo-irradiation
Number of subjects: 20
Study: 16012273

Group type: EXPERIMENTAL
Intervention: SSRI antidepressants
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: SNRI antidepressants
Number of subjects: 323
Study: 12651759

Group type: EXPERIMENTAL
Intervention: Amino acid tablets (Aminogran Food Supplement, UCB)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual protein substitute drinks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amino acid tablets
Number of subjects: 21
Study: 10820174

Group type: EXPERIMENTAL
Intervention: Furosemide 120 mg alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furosemide 120 mg plus sulfisoxazole
Number of subjects: 12
Study: 8700047

Group type: EXPERIMENTAL
Intervention: Head Position Monitor (HPM)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Force Platform (FP)
Number of subjects: 211
Study: 1519497

Group type: EXPERIMENTAL
Intervention: MLCu375
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: MLAgCu250
Number of subjects: 1790

Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 1790
Study: 6151343

Group type: EXPERIMENTAL
Intervention: Prizidilol (200 mg X 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg and 50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg X 2 and 50 mg X 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prizidilol (400 mg)
Number of subjects: 0
Study: 31866327

Group type: EXPERIMENTAL
Intervention: Isoniazid (5 mg/kg daily for 9 months)
Number of subjects: 6485

Group type: COMPARATOR
Intervention: Rifampicin (10 mg/kg daily for 4 months)
Number of subjects: 6485

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 6485

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 6485
Study: 31753004

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 17600

Group type: EXPERIMENTAL
Intervention: Relaxation intervention
Number of subjects: 17600

Group type: EXPERIMENTAL
Intervention: Strategies for Safety and Wellbeing
Number of subjects: 17600

Group type: COMPARATOR
Intervention: Usual provision (control)
Number of subjects: 17600
Study: 28744111

Group type: EXPERIMENTAL
Intervention: HCSMP-NHR (health-coaching self-management program)
Number of subjects: 90
Study: 26493075

Group type: COMPARATOR
Intervention: Neutral film
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Real trauma film
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Trauma 'reappraisal' film
Number of subjects: 105
Study: 24846707

Group type: EXPERIMENTAL
Intervention: Simulation training on pedicle screw placement in the ImmersiveTouch simulator
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional visual/verbal instruction (non-simulation)
Number of subjects: 26
Study: 21730017

Group type: EXPERIMENTAL
Intervention: SB-649868 (10-80 mg single dose)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: SB-649868 (5-30 mg multiple repeat dose)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: SB-649868 (evening dosing)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: SB-649868
Number of subjects: 103
Study: 18946429

Group type: EXPERIMENTAL
Intervention: Ketamine alone (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone alone (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thiopentone and ketamine combination (Group III)
Number of subjects: 60
Study: 17311602

Group type: COMPARATOR
Intervention: Ipratropium 40 microg by inhalation (positive control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral loperamide 4 mg
Number of subjects: 24
Study: 15724344

Group type: EXPERIMENTAL
Intervention: Coconut oil
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mineral oil
Number of subjects: 34
Study: 11294513

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel 1.25 g (0.75 mg E2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel 2.5 g (1.5 mg E2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel 0.625 g (0.375 mg E2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transdermal estradiol patch delivering 0.05 mg E2 per day
Number of subjects: 0